Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma 155Leukemia 127Precursor Cell Lymphoblastic Leukemia-Lymphoma 92Lymphoma, Non-Hodgkin 81Leukemia, Myeloid, Acute 80Lymphoma, Large B-Cell, Diffuse 75Multiple Myeloma 71Lymphoma, Follicular 64Hodgkin Disease 64Breast Neoplasms 64Leukemia, Lymphocytic, Chronic, B-Cell 63Lymphoma, Mantle-Cell 62Burkitt Lymphoma 60Myelodysplastic Syndromes 55Lymphoma, Large-Cell, Immunoblastic 53Sarcoma 41Lymphoma, B-Cell, Marginal Zone 40Neuroblastoma 37Central Nervous System Neoplasms 34Neoplasms, Plasma Cell 32Leukemia, Myeloid, Chronic-Phase 32Ovarian Neoplasms 31Leukemia, Myeloid, Accelerated Phase 30Myeloproliferative Disorders 28Dendritic Cell Sarcoma, Interdigitating 28Recurrence 27Congenital Abnormalities 27Blast Crisis 26Neutropenia 24Anemia, Refractory, with Excess of Blasts 22

Interventions

plerixafor 1ofatumumab 1Panzyga 1Lenalidomide 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Agammaglobulinemia × Filgrastim × Clear all
NCT02231879 2023-04-07

Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2/3 Completed
20 enrolled 10 charts

Agammaglobulinemia, Immunologic Deficiency Syndromes, Infections, Neutropenia, Warts

Data powered by HemOnc (CC BY 4.0) Colophon âš¡